Clinical Trial Phases Explained

When a new drug, vaccine, or medical device moves from the laboratory toward patients, it passes through a structured sequence of research phases. Each phase answers different questions and requires progressively larger groups of participants. Understanding this progression helps you assess what is known — and what is still unknown — about a treatment you or a family member is considering.

This page explains each trial phase and how it fits into the path to FDA approval. For an overview of what it means to participate in a trial, including informed consent and your rights as a participant, see the clinical trials and how research studies work guide.

Before Phase 1: the preclinical stage

Before any treatment is tested in humans, it goes through preclinical research — laboratory studies using cell cultures and animal models. Preclinical research examines whether the treatment has the intended biological effect, what doses produce that effect, and what initial toxicity looks like.

An Investigational New Drug (IND) application submitted to the FDA marks the transition from preclinical to human testing. The FDA reviews the application — which includes preclinical data, a proposed study design, and manufacturing information — and either approves human testing or places a clinical hold pending additional information.

Phase 1: establishing safety and dosing

Phase 1 trials are the first time a treatment is given to human participants. Their primary purpose is to evaluate safety, determine how the body processes the drug (pharmacokinetics), and identify a safe dose range.

Typical characteristics:

• Participants: 20 to 100 volunteers, often healthy volunteers (for non-cancer drugs) or patients with the target condition (common for oncology trials)
• Duration: several months to about a year
• Key questions: Is the treatment safe? What doses are tolerable? What are the early side effects? How does the body absorb, distribute, metabolize, and excrete it?

Phase 1 trials often use dose-escalation designs — participants receive progressively higher doses in sequential cohorts until a maximum tolerated dose is identified or pre-specified stopping rules are triggered.

Roughly 70 percent of treatments that enter Phase 1 move on to Phase 2, though this rate varies by disease area and treatment type.

Phase 2: testing for early evidence of efficacy

Phase 2 trials build on Phase 1 safety data and begin to ask whether the treatment works in patients with the target condition.

Typical characteristics:

• Participants: 100 to 300 patients with the condition being studied
• Duration: several months to a couple of years
• Key questions: Does the treatment show signs of efficacy? Which dose from Phase 1 is optimal? Are there new or more frequent side effects when given to the patient population rather than healthy volunteers?

Phase 2 trials may be randomized — participants are assigned to receive the treatment or a comparator — though many Phase 2 studies use a single arm (everyone receives the treatment) with historical comparison. Phase 2 results determine whether there is enough evidence of benefit to justify the larger, more expensive Phase 3 trial.

Phase	Primary focus	Typical participants
Phase 1	Safety, dosing, pharmacokinetics	20–100
Phase 2	Early efficacy, optimal dose, further safety	100–300
Phase 3	Comparative effectiveness, safety at scale	1,000–3,000+
Phase 4	Post-market safety and long-term effectiveness	Thousands to millions

Phase 3: comparative effectiveness at scale

Phase 3 trials are the pivotal studies that form the primary evidence base for FDA approval. They compare the experimental treatment directly against the current standard of care or a placebo, in a large and diverse population.

Typical characteristics:

• Participants: 1,000 to 3,000 or more, recruited across multiple clinical sites often in multiple countries
• Duration: one to several years depending on how long it takes to observe the outcomes being measured
• Design: almost always randomized and controlled; most are double-blind, meaning neither participants nor investigators know who received the treatment versus the comparator

Phase 3 trials are designed to detect differences in outcomes — survival rates, disease progression, symptom scores, quality of life — with enough statistical power to distinguish a real treatment effect from random variation. Regulatory agencies including the FDA require at least one (and usually two) successful Phase 3 trials demonstrating both efficacy and acceptable safety before approving a new treatment for widespread use.

FDA review and accelerated pathways

After successful Phase 3 trials, the drug manufacturer submits a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA. The FDA review period typically takes 6 to 12 months for standard reviews, or as few as 4 to 6 months under Priority Review designation for treatments addressing unmet medical needs.

Several pathways allow earlier access for serious conditions:

• Accelerated Approval — allows approval based on a surrogate endpoint (a measurable marker likely to predict the clinical benefit) while requiring a Phase 4 confirmatory trial
• Breakthrough Therapy Designation — intensive FDA guidance and interaction during development to expedite a treatment that shows substantial improvement over available therapy
• Fast Track Designation — more frequent FDA meetings and rolling review of sections of the application as they are completed

If you are considering a trial for a condition with limited treatment options, ask the study team whether the treatment has any of these designations and what that means for the development timeline.

Documents and terms you’ll see

When reading trial listings on ClinicalTrials.gov or a study’s consent form, watch for:

• Clinical trial — the overarching term for any interventional research study in humans; ClinicalTrials.gov lists trials by phase, condition, location, and recruitment status
• Randomized controlled trial — indicates that assignment to study arms is by chance; the most rigorous design for testing whether a treatment causes a given outcome
• Adverse event — any unwanted medical occurrence during a trial; reported on a scale from mild to serious; the consent form will describe how adverse events are monitored and reported in the specific study
• Placebo — a substance or procedure with no active ingredient; used in control arms so that participants and, in blinded trials, investigators cannot tell who received the real treatment

Phase 4: watching after approval

Once a treatment is approved and on the market, Phase 4 studies — post-market surveillance — continue to monitor its safety and effectiveness in real-world conditions. Phase 4 can involve:

• FDA-required post-market studies — the FDA sometimes conditions approval on the manufacturer completing specified post-market trials, particularly under Accelerated Approval
• Pharmacovigilance programs — systematic monitoring of adverse events reported by prescribers and patients through the FDA’s MedWatch system
• Registry studies — large databases tracking long-term outcomes in patients receiving the approved treatment
• Comparative effectiveness research — studies comparing the approved treatment to other available options outside the controlled trial environment

Phase 4 is where rare adverse events — those occurring in 1 in 10,000 patients or fewer — are most likely to be detected, because the trial population is now large enough for uncommon events to appear.

How to search for a trial

ClinicalTrials.gov is the federal registry where most U.S. trials must be registered. To search effectively:

1. Go to clinicaltrials.gov and enter your condition in the search box
2. Filter by Status: Recruiting to see only trials currently enrolling
3. Filter by Phase if you want to focus on a specific stage of research
4. Filter by Distance to find trials accessible to you geographically
5. Click a trial listing to read the eligibility criteria — each trial specifies inclusion criteria (who qualifies) and exclusion criteria (who does not)
6. Note the Contact information for the study team; they can answer questions before you decide whether to attend a screening visit

Many academic medical centers and cancer centers also maintain their own trial finder tools and have staff who can help match you to appropriate studies.